Watch for the ESMO 2026 presentation on October 24 for three-year durability data, especially the stand-alone therapy results. SITC 2026 oral presentation on November 6 may provide additional catalyst if systemic immune modulation data is compelling.
Price Chart
Executive Summary
Evaxion announced new immune data from its phase 2 trial of personalized cancer vaccine EVX-01 in advanced melanoma will be presented at SITC 2026 (oral and poster). The three-year clinical update is scheduled for ESMO 2026 on October 24. Prior two-year data showed a 75% ORR (12/16 patients) with 4 complete responses and 92% durable response at 2 years. This is a clinical-stage biotech with no approved products or reported revenue.
Key Facts
- New immune data for EVX-01 plus pembrolizumab to be presented at SITC 2026 (Nov 4-8) as both oral and poster presentation
- Three-year clinical data from phase 2 trial to be presented at ESMO 2026 on October 24, 2026
- Two-year data showed 75% ORR (12/16 patients), 4 complete responses, 92% still responding at 2 years with no relapses
- Third-year data will show EVX-01 as stand-alone therapy (without anti-PD-1 combination)
- 86% of EVX-01 neoantigen targets triggered tumor-specific immune response
- Evaxion is a clinical-stage TechBio company with no approved products or reported revenue
Financial Impact
No financial data provided; clinical-stage company with no revenue or guidance
Risk Factors
- Clinical-stage biotech with no approved products or revenue; requires additional capital
- Phase 2 trial has only 16 patients; results may not generalize to larger populations
- Third-year stand-alone data could show waning efficacy without pembrolizumab combination
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3373815 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 23, 2026 4d ago | 6-K | $3.76 $3.08 | ▼ −18.09% | ▼ −18.80% | $3.04 (−19.15%) |
Oct 19, 2026 8d ago | 6-K | $3.33 $4.05 | ▲ +21.62% | ▲ +21.29% | $3.04 (−8.71%) |
Oct 2, 2026 25d ago | 6-K | $3.20 $3.15 | ▼ −1.56% | ▼ −2.24% | $3.04 (−5.00%) |
Oct 2, 2026 25d ago | Press Release | $3.20 $3.15 | ▼ −1.56% | ▼ −2.24% | $3.04 (−5.00%) |
Sep 14, 2026 6w ago | 6-K | $3.07 $3.04 | ▼ −0.98% | ▼ −0.52% | $3.04 (−0.98%) |
Sep 4, 2026 7w ago | 6-K | $3.12 $3.17 | ▼ −1.60% | ▼ −2.15% | $3.04 (+2.56%) |
Aug 20, 2026 9w ago | 6-K | $3.28 $3.31 | ▲ +0.91% | ▲ +0.51% | $3.04 (−7.32%) |
Aug 20, 2026 9w ago | Press Release | $3.28 $3.31 | ▲ +0.91% | ▲ +0.51% | $3.04 (−7.32%) |
Aug 17, 2026 10w ago | 6-K | $3.13 $3.15 | ▲ +0.64% | ▲ +1.31% | $3.04 (−2.88%) |
Aug 14, 2026 10w ago | 6-K | $3.34 $3.13 | ▼ −6.29% | ▼ −5.81% | $3.04 (−8.98%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers